- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT06654752
Keuhkojen pahenemisvaiheiden virtaviivaistettu hoito pediatriassa (STOP PEDS RCT)
Keuhkojen pahenemisvaiheiden virtaviivainen hoito pediatriassa satunnaistettu kontrolloitu tutkimus (STOP PEDS RCT)
The STOP PEDS RCT is a multicenter, parallel, open label randomized controlled trial evaluating the long-term (one year) and short-term safety and efficacy of two antibiotic treatment strategies for the management of outpatient pulmonary exacerbations (PEx) in the pediatric CF population.
Tutkimuksen yleiskatsaus
Tila
Ehdot
Yksityiskohtainen kuvaus
The STOP PEDS pilot study demonstrated that a randomized trial of treatment strategies for mild pulmonary exacerbations (PEx) in children with CF was feasible and that assignment to a tailored therapy arm (defined below) may reduce antibiotic exposure.
Based on the research priorities identified by CF families and clinicians and the results of the pilot study, the STOP PEDS RCT is a multicenter, parallel, open label randomized controlled trial evaluating the long-term (one year) and short-term safety and efficacy of two antibiotic treatment strategies for the management of outpatient PEx in the pediatric CF population. The two treatment arms are immediate antibiotics and tailored therapy. In both arms, participants will be instructed to increase airway clearance at the onset of an eligible PEx. In the immediate antibiotics arm, they will also begin 14 days of oral antibiotics preselected by their primary CF providers, while in the tailored therapy they will only begin antibiotics if prespecified criteria for worsening symptoms or failure to improve are met.
The STOP PEDS study will enroll three cohorts. In the main cohort, children ages 6-18 on highly effective modulator therapy (HEMT) will be enrolled when well and followed for 12 months. Participants will be randomly assigned to a treatment arm and maintain that treatment assignment for all subsequent eligible PEx during their 12-month enrollment period. Two additional pilot cohorts, the preschool cohort (children ages 3 to 5 on HEMT) and the non-HEMT cohort (children ages 6-18 not eligible for HEMT), will be enrolled in parallel pilot studies. Participants will enroll when well and be followed through one randomized PEx.
Participants in the STOP PEDS RCT at selected sites will have the opportunity to enroll in optional substudies if eligible. These substudies include:
- Clinic throat swab substudy
- Home throat and nasal swab substudy
- Remote monitoring substudy (Home monitoring of lung function, vital signs, activity and sleep)
Opintotyyppi
Ilmoittautuminen (Arvioitu)
Vaihe
- Ei sovellettavissa
Yhteystiedot ja paikat
Opiskeluyhteys
- Nimi: Erika Enright
- Puhelinnumero: 206-897-1922
- Sähköposti: eenright@uw.edu
Opiskelupaikat
-
-
British Columbia
-
Vancouver, British Columbia, Kanada, V6H 3V4
- Rekrytointi
- British Columbia Children's Hospital
-
Päätutkija:
- Jonathan Rayment, MD
-
Ottaa yhteyttä:
- Ronak S Ravandi
- Sähköposti: ronak.salamatravandi@bcchr.ca
-
-
Ontario
-
Toronto, Ontario, Kanada, M5G 0A4
- Rekrytointi
- The Hospital for Sick Children & Toronto Canada CF Centre Pediatrics
-
Päätutkija:
- Felix Ratjen, MD
-
Ottaa yhteyttä:
- Claire Crompton
- Sähköposti: claire.crompton@sickkids.ca
-
-
-
-
Alabama
-
Birmingham, Alabama, Yhdysvallat, 35233
- Rekrytointi
- The Children's Hospital Alabama & University of Alabama at Birmingham
-
Päätutkija:
- Christopher Fowler, MD
-
Ottaa yhteyttä:
- Valerie Tarn
- Puhelinnumero: 2056385134
- Sähköposti: vtarn@uabmc.edu
-
-
Arizona
-
Tucson, Arizona, Yhdysvallat, 85713
- Rekrytointi
- Tucson Cystic Fibrosis Center
-
Päätutkija:
- Cori Daines, MD
-
Ottaa yhteyttä:
- Elizabeth (Lisa) Ryan
- Sähköposti: elizabethryan@arizona.edu
-
-
California
-
Los Angeles, California, Yhdysvallat, 90027
- Rekrytointi
- Children's Hospital of Los Angeles & Anton Yelchin Cystic Fibrosis Clinic
-
Päätutkija:
- Martha McKinney, MD
-
Ottaa yhteyttä:
- Ariana Teame, BA
- Sähköposti: ateame@chla.usc.edu
-
Palo Alto, California, Yhdysvallat, 94304
- Rekrytointi
- Stanford University
-
Ottaa yhteyttä:
- Tina Conti, BSRC, RRT, RRT-NPS, C-NPT
- Sähköposti: tconti@stanford.edu
-
Päätutkija:
- Lori WaiHang Lee, MD
-
San Diego, California, Yhdysvallat, 92123
- Ei vielä rekrytointia
- Rady Children's Hospital at University of California San Diego
-
Ottaa yhteyttä:
- Lisa Ramos, CRC
- Sähköposti: lramosvallejo@health.ucsd.edu
-
Päätutkija:
- Kathryn Akong, MD
-
-
Colorado
-
Aurora, Colorado, Yhdysvallat, 80045
- Rekrytointi
- Children's Hospital of Colorado
-
Päätutkija:
- Jordana Hoppe, MD
-
Ottaa yhteyttä:
- Mary Cross
- Sähköposti: Mary.Cross@childrenscolorado.org
-
-
Georgia
-
Atlanta, Georgia, Yhdysvallat, 30322
- Rekrytointi
- Children's Healthcare of Atlanta & Emory University
-
Ottaa yhteyttä:
- Joy Dangerfield
- Sähköposti: jdanger@emory.edu
-
Päätutkija:
- Ajay Kasi, MD
-
-
Illinois
-
Chicago, Illinois, Yhdysvallat, 60611
- Rekrytointi
- Ann & Robert H. Lurie Children's Hospital of Chicago & Northwestern University
-
Päätutkija:
- Maria Dowell, MD
-
Ottaa yhteyttä:
- Lisa Gallo, CRC
- Puhelinnumero: 312-227-2473
- Sähköposti: lgallo@luriechildrens.org
-
-
Indiana
-
Indianapolis, Indiana, Yhdysvallat, 46202
- Rekrytointi
- Riley Hospital for Children & Indiana University
-
Ottaa yhteyttä:
- Lisa Bendy
- Sähköposti: lbendy@iu.edu
-
Päätutkija:
- D. B. Sanders, MD, MS
-
Ottaa yhteyttä:
- Misty Thompson
- Sähköposti: misthomp@iu.edu
-
-
Iowa
-
Iowa City, Iowa, Yhdysvallat, 52242
- Rekrytointi
- University of Iowa
-
Ottaa yhteyttä:
- Mary Teresi
- Sähköposti: mary-teresi@uiowa.edu
-
Päätutkija:
- Anthony Fischer, MD
-
-
Maryland
-
Baltimore, Maryland, Yhdysvallat, 21287
- Rekrytointi
- Johns Hopkins Hospital, Johns Hopkins University
-
Ottaa yhteyttä:
- Jamelia Maynard
- Sähköposti: jmaynar8@jhmi.edu
-
Päätutkija:
- Peter Mogayzel, MD, PhD, MBA
-
-
Massachusetts
-
Boston, Massachusetts, Yhdysvallat, 02115
- Rekrytointi
- Boston Children's Hospital & Harvard University
-
Ottaa yhteyttä:
- Monica Ulles
- Sähköposti: monica.ulles@childrens.harvard.edu
-
Päätutkija:
- Gregory Sawicki, MD
-
-
Michigan
-
Ann Arbor, Michigan, Yhdysvallat, 48109-5212
- Rekrytointi
- University of Michigan Health System
-
Ottaa yhteyttä:
- Dawn Kruse
- Sähköposti: dmkruse@med.umich.edu
-
Päätutkija:
- Samya Nasr, MD
-
-
Minnesota
-
Minneapolis, Minnesota, Yhdysvallat, 55404
- Rekrytointi
- Children's Hospitals and Clinics of Minnesota
-
Päätutkija:
- Brooke Moore, MD
-
Ottaa yhteyttä:
- Danniella Balangoy
- Sähköposti: Danniella.Balangoy@childrensmn.org
-
Minneapolis, Minnesota, Yhdysvallat, 55455
- Rekrytointi
- The Minnesota Cystic Fibrosis Center & University of Minnesota
-
Päätutkija:
- Samuel Goldfarb, MD
-
Ottaa yhteyttä:
- Alyssa Perry
- Sähköposti: ahperry@umn.edu
-
-
Missouri
-
Kansas City, Missouri, Yhdysvallat, 64108
- Rekrytointi
- Children's Mercy Hospital
-
Ottaa yhteyttä:
- Jana Lomonte
- Sähköposti: jblomonte@cmh.edu
-
Päätutkija:
- Hugo Escobar, MD
-
St Louis, Missouri, Yhdysvallat, 63110
- Rekrytointi
- St. Louis Children's Hospital & Washington University School of Medicine
-
Päätutkija:
- Jessica Pittman, MD
-
Ottaa yhteyttä:
- Taylor Haas, RN, BSN
- Sähköposti: koenigt@wustl.edu
-
-
New York
-
Rochester, New York, Yhdysvallat, 14642
- Rekrytointi
- University of Rochester Medical Center Strong Memorial
-
Ottaa yhteyttä:
- Barbara Johnson, RN
- Sähköposti: Barbara_johnson@urmc.rochester.edu
-
Päätutkija:
- Matthew McGraw, MD
-
-
North Carolina
-
Chapel Hill, North Carolina, Yhdysvallat, 27514
- Rekrytointi
- University of North Carolina at Chapel Hill
-
Päätutkija:
- Jennifer Goralski, MD
-
Ottaa yhteyttä:
- Caroline Flowers, CRC
- Sähköposti: caroline_flowers@med.unc.edu
-
-
Ohio
-
Cincinnati, Ohio, Yhdysvallat, 45229
- Rekrytointi
- Cincinnati Children's Hospital Medical Center
-
Päätutkija:
- Gary McPhail, MD
-
Ottaa yhteyttä:
- Sharon Donnelly, RN, BSN, CPN
- Sähköposti: sharon.kadon@cchmc.org
-
-
Oregon
-
Portland, Oregon, Yhdysvallat, 97239-3098
- Rekrytointi
- Oregon Health & Science University
-
Ottaa yhteyttä:
- Pierce Nusbaum
- Sähköposti: nusbaum@ohsu.edu
-
Päätutkija:
- Kelvin MacDonald, MD
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Yhdysvallat, 19104
- Rekrytointi
- Children's Hospital of Philadelphia & University of Pennsylvania
-
Päätutkija:
- Clement Ren, MD, MBA
-
Ottaa yhteyttä:
- Matthew Gari
- Sähköposti: garim@chop.edu
-
Ottaa yhteyttä:
- Erin Donnelly
- Sähköposti: donnellye4@chop.edu
-
Pittsburgh, Pennsylvania, Yhdysvallat, 15224
- Rekrytointi
- Children's Hospital of Pittsburgh of UPMC & University of Pittsburgh Medical Center
-
Päätutkija:
- Daniel Weiner, MD
-
Ottaa yhteyttä:
- Tyler Johnston, RN
- Sähköposti: ateame@chla.usc.edu
-
-
South Carolina
-
Charleston, South Carolina, Yhdysvallat, 29425
- Rekrytointi
- Medical University of South Carolina
-
Päätutkija:
- Sylvia E Szentpeter, MD
-
Ottaa yhteyttä:
- Anushka Phadke, CRC
- Puhelinnumero: 843-792-4656
- Sähköposti: phadke@musc.edu
-
Ottaa yhteyttä:
- Sarah Shine, CRC
- Puhelinnumero: 843-792-1221
- Sähköposti: shinesa@musc.edu
-
-
Texas
-
Dallas, Texas, Yhdysvallat, 75235
- Rekrytointi
- University of Texas Southwestern & Children's Health
-
Päätutkija:
- Preeti Sharma, MD
-
Ottaa yhteyttä:
- Lindsay Allen, CRC
- Sähköposti: Lindsay.Allen@utsouthwestern.edu
-
Houston, Texas, Yhdysvallat, 77030
- Rekrytointi
- Texas Children's Hospital & Baylor College of Medicine
-
Päätutkija:
- Fadel Ruiz, MD
-
Ottaa yhteyttä:
- Mayel Yepez
- Sähköposti: Mayel.YepezDonado@bcm.edu
-
-
Vermont
-
Burlington, Vermont, Yhdysvallat, 05401
- Rekrytointi
- Vermont Children's Hospital & University of Vermont Medical Center
-
Päätutkija:
- Thomas Lahiri, MD
-
Ottaa yhteyttä:
- Zachary Dichard
- Sähköposti: Zachary.Dichard@uvmhealth.org
-
-
Virginia
-
Richmond, Virginia, Yhdysvallat, 23298
- Rekrytointi
- Virginia Commonwealth University
-
Ottaa yhteyttä:
- Aleksander Subotic, CRC
- Sähköposti: aleksandar.subotic@vcuhealth.org
-
Päätutkija:
- Michael T. Schechter, MD
-
-
Washington
-
Seattle, Washington, Yhdysvallat, 98105
- Rekrytointi
- Seattle Children's Hospital
-
Päätutkija:
- Margaret Rosenfeld, MD
-
Ottaa yhteyttä:
- Marissa Nelson, CRC
- Puhelinnumero: 206-987-3921
- Sähköposti: marissa.nelsen@seattlechildrens.org
-
Ottaa yhteyttä:
- Elizabeth Gore, RN, MPH
- Puhelinnumero: 206-987-3317
- Sähköposti: Liz.Gore@seattlechildrens.org
-
-
Wisconsin
-
Madison, Wisconsin, Yhdysvallat, 53792
- Rekrytointi
- University of Wisconsin
-
Päätutkija:
- Hara Levy, MD
-
Ottaa yhteyttä:
- Nikki Cole, BS, RRT, CCRC
- Sähköposti: ndondlinger@wisc.edu
-
Milwaukee, Wisconsin, Yhdysvallat, 53226
- Rekrytointi
- Children's Wisconsin & Medical College of Wisconsin
-
Päätutkija:
- Nicholas Antos, MD
-
Ottaa yhteyttä:
- Laura Robertson, CCRC
- Sähköposti: lrobertson@mcw.edu
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
-
Age
- For main cohort and non-HEMT cohort: age 6 to <19 years
- For preschool cohort: age 3 to <6 years
-
Documentation of a CF diagnosis as evidenced by one or more clinical features consistent with the CF phenotype and one or more of the following criteria:
- sweat chloride ≥ 60 mEq/liter
- two disease-causing variants in the cystic fibrosis transmembrane conductive regulator (CFTR) gene
-
Written informed consent (and assent when applicable) obtained from participant or participant's legal representative and ability of participant to comply with the requirements of the study
-
Highly Effective Modulator Therapy
- For main cohort and preschool cohort: Taking HEMT for at least 3 months at enrollment
- For non-HEMT cohort: not eligible for HEMT based on CFTR genotype or eligible but not taking for at least 3 months and no plans to start HEMT in the next year, and also not taking tezacaftor-ivacaftor or lumacaftor-ivacaftor for at least 3 months
-
For main cohort and non-HEMT cohort: able to perform acceptable and reproducible spirometry
-
For main cohort and non-HEMT cohort: ppFEV1 ≥ 50% predicted at enrollment based on the Global lung Initiative (GLI) reference equations
-
Ability to receive text messages and access the internet
Exclusion Criteria:
- Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the individual or the quality of the data
- Receiving an acute course of oral or IV antibiotics at the time of enrollment or within the 14 days prior to enrollment. Individuals may be re-screened ≥21 days after completion of antibiotics if they are at their baseline state of health, per self-report
- Treatment with systemic corticosteroids at enrollment or within the 14 days prior to enrollment. Individuals may be re- screened ≥21 days after completion of systemic corticosteroids if they are at their clinical baseline, per self-report
- History of solid organ transplant
- History of positive culture for Mycobacterium abscessus in the 12 months prior to enrollment
- Treatment with antibiotics for any non-tuberculous mycobacteria (NTM) at enrollment
- Three or more IV antibiotic-treated PEx in the 12 months prior to enrollment
- Treatment with chronic oral antibiotics other than azithromycin at enrollment
- Treatment with systemic corticosteroids for allergic bronchopulmonary aspergillosis (ABPA) in the 12 months prior to enrollment
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Satunnaistettu
- Inventiomalli: Rinnakkaistehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Kokeellinen: Immediate Antibiotics
Increased airway clearance plus early initiation of oral antibiotics |
Increase airway clearance and start 14 days of preselected oral antibiotics right away |
|
Kokeellinen: Tailored Therapy
Increased airway clearance alone, with addition of oral antibiotics for worsening symptoms or failure to improve |
Increase airway clearance and start preselected oral antibiotics later if symptoms get worse or do not get better according to prespecified criteria |
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
One-year change in pulmonary function by spirometry-measured ppFEV1
Aikaikkuna: 1 year
|
Compare the difference in pulmonary function between arms by evaluating change in spirometry-measured percent predicted forced expiratory volume (ppFEV1). A spirometry test measures the amount of air a person can forcibly exhale after a deep breath (forced vital capacity, or FVC) and the amount of air they can exhale in one second (forced expiratory volume in one second, or FEV1). A lower measured value compared to the reference value indicates lung disease. |
1 year
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
One-Year change in pulmonary function by LCI
Aikaikkuna: 1 year
|
Compare the difference in pulmonary function between arms by evaluating change in Lung Clearance Index (LCI). LCI increases when there is lung disease, which causes ventilation inhomogeneity. LCI is calculated as the number of lung volume turnovers (cumulative expired volume divided by the functional residual capacity [FRC]) required to reduce end-tidal nitrogen concentration to 1/40th of the original level. |
1 year
|
Muut tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Recovery to baseline by ppFEV1 and CRISS following a PEx
Aikaikkuna: 28 days
|
Compare recovery to baseline between arms over the 28-day period after the first pulmonary exacerbation (PEx), by spirometry-measured percent predicted forced expiratory volume (ppFEV1), and after all pulmonary exacerbations, measured by CRISS symptom scores. The Chronic Respiratory Infection Symptom Score (CRISS) ranges from 0 to 100, with higher scores indicating more symptoms. |
28 days
|
|
Recovery to baseline by Lung Clearance Index (LCI)
Aikaikkuna: 28 days
|
Compare recovery to baseline between arms over the 28-day period after the first pulmonary exacerbation (PEx) in LCI, and after all exacerbations for symptom scores. The Chronic Respiratory Infection Symptom Score (CRISS) ranges from 0 to 100, with higher scores indicating more symptoms. |
28 days
|
|
Safety Endpoint 1: Cumulative oral antibiotic exposure
Aikaikkuna: 1 year
|
Compare cumulative oral antibiotic exposure in each treatment arm. |
1 year
|
|
Safety Endpoint 2: Number of respiratory illnesses
Aikaikkuna: 1 year
|
Compare the number of respiratory illnesses reported over the study period in each treatment arm. |
1 year
|
|
Safety Endpoint 3: Proportion of respiratory illnesses treated with antibiotics during PEx
Aikaikkuna: 28 days
|
Compare the proportion of respiratory illnesses treated with antibiotics during the 28-day pulmonary exacerbation (PEx) treatment period in each treatment arm. |
28 days
|
|
Safety Endpoint 4: Number of PEx treated with IV antibiotics
Aikaikkuna: 1 year
|
Compare the number of pulmonary exacerbations (PEx) treated with IV antibiotics over the study period in each treatment arm. |
1 year
|
|
Safety Endpoint 5: Proportion of PEx failing to recover to baseline symptoms at Day 28
Aikaikkuna: 28 days
|
Compare the proportion of pulmonary exacerbations (PEx) failing to recover to baseline symptoms at Day 28 in each treatment arm. |
28 days
|
|
Safety Endpoint 6: Proportion of PEx with ppFEV1 below baseline at Day 28
Aikaikkuna: 1 year
|
Compare the proportion of pulmonary exacerbations (PEx) with spirometry-measured percent predicted forced expiratory volume (ppFEV1) below baseline at Day 28 in each treatment arm. |
1 year
|
|
Safety Endpoint 7: Time from initial randomized PEx to next respiratory illness
Aikaikkuna: 1 year
|
Compare the time from initial randomized pulmonary exacerbation (PEx) to next respiratory illness in each treatment arm. |
1 year
|
|
Safety Endpoint 8: Targeted adverse events (patient report of antibiotic side effects during PEx)
Aikaikkuna: 1 year
|
Compare the targeted adverse events (patient report of antibiotic side effects during pulmonary exacerbation period) in each treatment arm. |
1 year
|
|
Safety Endpoint 9: Treatment-emergent CF microorganisms on clinical respiratory cultures
Aikaikkuna: 1 year
|
Compare treatment-emergent CF microorganisms on clinical respiratory cultures in each treatment arm. |
1 year
|
|
Qualitative Assessment 1: Caregivers' experience managing study treatment
Aikaikkuna: 1 year
|
To understand benefits and challenges associated with assigned treatment through targeted qualitative interviews of caregivers we will describe caregivers' experience managing study treatment and report themes that emerge regarding caregivers' experiences. |
1 year
|
|
Qualitative Assessment 2: Study treatment impact on child and family daily life
Aikaikkuna: 1 year
|
To understand benefits and challenges associated with assigned treatment through targeted qualitative interviews of caregivers we will evaluate study treatment impact on child and family daily life and report themes that emerge regarding caregivers' experiences. |
1 year
|
|
Health care costs 1: Total estimated cost of antibiotics
Aikaikkuna: 1 year
|
Compare total estimated cost of antibiotics used over the course of the study between treatment arms. |
1 year
|
|
Health care costs 2: Health care utilization
Aikaikkuna: 1 year
|
Compare health care utilization over the course of the study between treatment arms, including number of primary care visits and number of emergency room visits. |
1 year
|
|
Health care costs 3: Parent work productivity measures (WPAI)
Aikaikkuna: 1 year
|
To compare parent Work Productivity and Activity Impairment (WPAI) measures between study arms. The WPAI includes four scores assessing absenteeism, presenteeism, work productivity loss (overall work impairment/absenteeism plus presenteeism), and activity impairment in the last seven days. Scores range from 0 to 100, with higher scores indicating greater impairment. |
1 year
|
|
Preschool and non-HEMT Pilot Cohort Primary Feasibility
Aikaikkuna: 28 days
|
Estimate the proportion of preschool and non-HEMT (Highly Effective Modulator Therapy) participants randomized to the tailored therapy arm that has no antibiotic exposure in the 28 days following a pulmonary exacerbation (PEx). |
28 days
|
|
Preschool and non-HEMT Pilot Cohort Safety Endpoint 1: ppFEV1 and LCI recovery
Aikaikkuna: 28 days
|
Compare percent predicted forced expiratory volume (ppFEV1) and Lung Clearance Index (LCI) recovery using Day 28 values compared to nearest pre-PEx baseline measure in both treatment arms. |
28 days
|
|
Preschool and non-HEMT Pilot Cohort Safety Endpoint 2: Time to symptom recovery
Aikaikkuna: 28 days
|
Compare time to symptom recovery (number of days to recover to baseline CRISS score) between treatment arms. The Chronic Respiratory Infection Symptom Score (CRISS) ranges from 0 to 100, with higher scores indicating more symptoms. |
28 days
|
|
Preschool and non-HEMT Pilot Cohort Safety Endpoint 3: Targeted adverse events
Aikaikkuna: 28 days
|
Compare targeted adverse events (participant report of antibiotic side effects during PEx period) between treatment arms. |
28 days
|
|
Preschool and non-HEMT Pilot Cohort Safety Endpoint 4: Treatment-emergent CF microorganisms
Aikaikkuna: 28 days
|
Compare treatment-emergent CF microorganisms on clinical respiratory cultures between treatment arms. |
28 days
|
|
Preschool and non-HEMT Pilot Cohort Safety Endpoint 5: Treatment with additional non-protocol assigned antibiotics
Aikaikkuna: 28 days
|
Compare treatment with additional non-protocol assigned antibiotics within the 28 days post-randomization between treatment arms. |
28 days
|
|
Preschool and non-HEMT Pilot Cohort Safety Endpoint 6: Time to IV antibiotics following a randomized PEx
Aikaikkuna: 28 days
|
Compare time to IV antibiotics following a randomized PEx (using CF Foundation Patient Registry data, if available) between treatment arms. |
28 days
|
|
Preschool and non-HEMT Pilot Cohort: Future Larger Clinical Trial Feasibility 1
Aikaikkuna: 28 days
|
Measure the proportion of approached patients that enrolls. |
28 days
|
|
Preschool and non-HEMT Pilot Cohort: Future Larger Clinical Trial Feasibility 2
Aikaikkuna: 28 days
|
Measure the proportion of respiratory symptoms meeting randomization criteria. |
28 days
|
|
Preschool and non-HEMT Pilot Cohort: Future Larger Clinical Trial Feasibility 3
Aikaikkuna: 28 days
|
Measure the proportion of respiratory symptoms meeting randomization criteria resulting in treatment initiation within assigned arm. |
28 days
|
|
Preschool and non-HEMT Pilot Cohort: Future Larger Clinical Trial Feasibility 4
Aikaikkuna: 28 days
|
Through targeted qualitative interviews of caregivers we will describe caregivers' experience managing study treatment and report themes that emerge regarding caregivers' experiences in order to understand motivations, benefits and challenges associated with assigned treatment arm. |
28 days
|
|
Clinic Throat Swab Substudy 1: Metagenomic Sequencing
Aikaikkuna: 1 year
|
Use quantitative polymerase chain reaction (qPCR) and metagenomic sequencing to quantitatively define throat swab microbiology at baseline, at exacerbation diagnosis, and after treatment. Metagenomic sequencing analyzes the genomes of all microorganisms in a sample, providing a broad overview of the ecosystem's composition. It can be used to study the diversity of bacteria, detect the abundance of microbes, and study unculturable microorganisms. |
1 year
|
|
Clinic Throat Swab Substudy 2: Microbiota Measures
Aikaikkuna: 1 year
|
Correlate throat microbiota measures (both pre-treatment microbial taxonomic or functional gene abundances, and changes in those abundances) with clinical outcome measures within antibiotic treatments. |
1 year
|
|
Home Throat and Nasal Swab Substudy 1: Feasibility of Home Collection of Nasal Swabs for Viral Testing and Illness Frequency
Aikaikkuna: 28 days
|
Assess the feasibility of home collection of nasal swabs for viral testing at the time of pulmonary exacerbation (PEx) and determine the frequency of viral illness at the time of PEx diagnosis. |
28 days
|
|
Home Throat and Nasal Swab Substudy 2: Feasibility of Home Collection of Throat Swabs for Bacterial testing
Aikaikkuna: 28 days
|
Assess the feasibility of home collection of throat swabs for bacterial testing at the time of pulmonary exacerbation (PEx). |
28 days
|
|
Home Throat and Nasal Swab Substudy 3: Association Between Viral Illness and Symptom recovery
Aikaikkuna: 28 days
|
Evaluate the association between the presence of viral illness and symptom recovery (number of days to recover to baseline CRISS score) between treatment arms. The Chronic Respiratory Infection Symptom Score (CRISS) ranges from 0 to 100, with higher scores indicating more symptoms. |
28 days
|
|
Home Throat and Nasal Swab Substudy 3: Association Between Viral Illness and FEV1
Aikaikkuna: 28 days
|
Evaluate the association between the presence of viral illness and spirometry-measured forced expiratory volume (FEV1) at Day 28. |
28 days
|
|
Home Throat and Nasal Swab Substudy 3: Association Between Viral Illness and antibiotic treatment.
Aikaikkuna: 28 days
|
Evaluate the association between the presence of viral illness and the percent of subjects in the tailored therapy arm requiring antibiotic treatment. |
28 days
|
|
Home Throat and Nasal Swab Substudy 5: Bacterial Pathogen Identification, Frequency and Impact on Treatment Changes
Aikaikkuna: 28 days
|
Determine the concordance of bacteria identified on CF pathogen testing at the time of pulmonary exacerbation (PEx) compared to the most recent routine clinic visit. In addition, assess how frequently new bacterial pathogens are identified at the time of PEx and how this impacts treatment changes, including the need to change or add antibiotic therapy. |
28 days
|
|
Remote Monitoring Substudy 1: Feasibility of Home Spirometry Use During PEx
Aikaikkuna: 28 days
|
Describe the feasibility and user acceptability of home spirometry during pulmonary exacerbations (PEx) in children with CF via survey of participants at the end of the study. |
28 days
|
|
Remote Monitoring Substudy 2: Feasibility of BioButton Use During PEx
Aikaikkuna: 14 days
|
Describe the feasibility and user acceptability of BioButton use during pulmonary exacerbations in children with CF via survey of participants at the end of the study. |
14 days
|
|
Remote Monitoring Substudy 3: Change in FEV1 by Home Spirometry
Aikaikkuna: 28 days
|
Describe the change from nearest baseline-state FEV1 to Day 0 exacerbation state measurement and the trajectory of change during the exacerbation state (through Day 28). |
28 days
|
|
Remote Monitoring Substudy 4: Compare Home Spirometry vs. Clinic Spirometry Measures
Aikaikkuna: 28 days
|
Compare measurements and their change measured by home spirometry vs. clinic spirometry during the exacerbation state. |
28 days
|
|
Remote Monitoring Substudy 5: BioButton-measured Change in Resting Heart Rate During PEx
Aikaikkuna: 14 days
|
Describe changes in resting heart rate from Day 0 to 14 of the exacerbation state. |
14 days
|
|
Remote Monitoring Substudy 5: BioButton-measured Change in Resting respiratory rate During PEx
Aikaikkuna: 14 days
|
Describe changes in Resting respiratory rate from Day 0 to 14 of the exacerbation state. |
14 days
|
|
Remote Monitoring Substudy 5: BioButton-measured Change in Activity Level During PEx
Aikaikkuna: 14 days
|
Describe changes activity level, measured using actigraphy, and summarized as the mean (SD) number of active minutes in a day, from Day 0 to 14 of the exacerbation state. |
14 days
|
|
Remote Monitoring Substudy 5: BioButton-measured Change in Sleep During PEx
Aikaikkuna: 14 days
|
Describe changes in sleep time from Day 0 to 14 of the exacerbation state. |
14 days
|
|
Remote Monitoring Substudy 6: Compare BioButton-measured Change in resting heart rate During PEx with Baseline Averages
Aikaikkuna: 14 days
|
Compare changes in resting HR to averages from a 7-day period during baseline state. |
14 days
|
|
Remote Monitoring Substudy 6: Compare BioButton-measured Change in Resting respiratory rate During PEx with Baseline Averages
Aikaikkuna: 14 days
|
Compare changes in BioButton-measured Resting respiratory rate to averages from a 7-day period during baseline state. |
14 days
|
|
Remote Monitoring Substudy 6: Compare BioButton-measured Change in activity level During PEx with Baseline Averages
Aikaikkuna: 14 days
|
Compare BioButton-measured change in activity level during pulmonary exacerbation (PEx) to averages from a 7-day period during baseline state. |
14 days
|
|
Remote Monitoring Substudy 6: Compare BioButton-measured Change in Sleep During PEx with Baseline Averages
Aikaikkuna: 14 days
|
Compare BioButton change in sleep during PEx to averages from a 7-day period during baseline state. |
14 days
|
|
Remote Monitoring Substudy 7: Determine correlations between changes in FEV1 and CRISS to Resting Heart Rate (HR)
Aikaikkuna: 14 days
|
Determine correlations between changes from Day 0 to 14 in forced expiratory volume (FEV1) and CRISS score to Resting Heart Rate (HR). The Chronic Respiratory Infection Symptom Score (CRISS) ranges from 0 to 100, with higher scores indicating more symptoms. |
14 days
|
|
Remote Monitoring Substudy 7: Determine correlations between changes in FEV1 and CRISS to Resting Respiratory rate
Aikaikkuna: 14 days
|
Determine correlations between changes from Day 0 to 14 in forced expiratory volume (FEV1) and CRISS score to Resting Respiratory rate. The Chronic Respiratory Infection Symptom Score (CRISS) ranges from 0 to 100, with higher scores indicating more symptoms. |
14 days
|
|
Remote Monitoring Substudy 7: Determine correlations between changes in FEV1 and CRISS to Activity level
Aikaikkuna: 14 days
|
Determine correlations between changes from Day 0 to 14 in forced expiratory volume (FEV1) and CRISS score to Activity level, measured with actigraphy. The Chronic Respiratory Infection Symptom Score (CRISS) ranges from 0 to 100, with higher scores indicating more symptoms. |
14 days
|
|
Remote Monitoring Substudy 7: Determine correlations between changes in FEV1 and CRISS to Sleep duration
Aikaikkuna: 14 days
|
Determine correlations between changes from Day 0 to 14 in forced expiratory volume (FEV1) and CRISS score to sleep duration. The Chronic Respiratory Infection Symptom Score (CRISS) ranges from 0 to 100, with higher scores indicating more symptoms. |
14 days
|
Yhteistyökumppanit ja tutkijat
Yhteistyökumppanit
Tutkijat
- Päätutkija: Margaret Rosenfeld, MD, MPH, Seattle Children's Hospital
- Päätutkija: D. B. Sanders, MD, MS, Indiana University
Julkaisuja ja hyödyllisiä linkkejä
Hyödyllisiä linkkejä
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Ensisijainen valmistuminen (Arvioitu)
Opintojen valmistuminen (Arvioitu)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muita asiaankuuluvia MeSH-ehtoja
Muut tutkimustunnusnumerot
- STOP PEDS RCT
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .